Medicare Enrolled
Dr. Dally Legaspi, APRN, FNP-C
Physician Assistant · Ocala, FL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Legaspi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Legaspi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Legaspi
Dr. Dally Legaspi is a physician assistant in Ocala, FL, with 6 years of NPI registration. Based on federal Medicare data, Dr. Legaspi performed 25,348 Medicare services across 768 unique beneficiaries.
Between the years covered by Open Payments, Dr. Legaspi received a total of $11,124 from 73 pharmaceutical and/or device companies across 545 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in physician assistant. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Legaspi is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 6 years in practice
▲ Top 0% volume in FL
$11,124 industry payments
Florida License Status
FL DOH · MQA2
Active licenses
None
Board action on record
0
Recent admin complaints
| Profession | License # | Status | Expires | Board Action |
|---|---|---|---|---|
| Registered Nurse | 9531520 | Clear | April 30, 2027 | — |
| Advanced Practice Registered Nurse | 11006318 | Clear | April 30, 2027 | — |
Data from Florida Department of Health Medical Quality Assurance.
License records are public under Chapter 119, Florida Statutes.
Verify directly on FL DOH →
Medicare Practice Summary
Medicare Utilization ↗25,348
Medicare services
Top 0% in FL for physician assistant
768
Unique beneficiaries
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~4,225 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
9,000 | $2 | $21 |
| Filgrastim injection (Zarxio) for white blood cells An injection of the biosimilar medication filgrastim-sndz (Zarxio) with a dosage of 1 microgram. |
8,640 | $0 | $2 |
| Immune globulin infusion (Octagam) This procedure involves the administration of immune globulin medication directly into a vein. It is provided in a non-lyophilized liquid form. |
2,860 | $34 | $252 |
| Iron infusion (Monoferric) | 1,900 | $17 | $75 |
| Denosumab injection (Prolia/Xgeva) | 1,500 | $19 | $71 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
280 | $0 | $1 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
261 | $56 | $148 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
202 | $81 | $224 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
185 | $9 | $93 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
114 | $10 | $105 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
96 | $40 | $304 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
73 | $84 | $686 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
61 | $13 | $97 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
52 | $1 | $19 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
49 | $1 | $7 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
34 | $21 | $249 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
23 | $1 | $19 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
18 | $94 | $343 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
19.9% high complexity
78.2% medium
1.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$11,124
Total received (2021-2024)
Avg $2,781/year across 4 years
Top 2% in FL for physician assistant
73
Companies
545
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,964 (98.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$160 (1.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,556
2023
$3,181
2022
$2,924
2021
$1,464
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$629
Novartis Pharmaceuticals Corporation
$596
Janssen Biotech, Inc.
$557
Merck Sharp & Dohme LLC
$548
PFIZER INC.
$452
Seagen Inc.
$404
Daiichi Sankyo Inc.
$353
Incyte Corporation
$346
Astellas Pharma US Inc
$326
JAZZ PHARMACEUTICALS INC.
$321
Eisai Inc.
$321
Celgene Corporation
$320
Amgen Inc.
$307
Genmab U.S., Inc.
$290
Genentech USA, Inc.
$288
E.R. Squibb & Sons, L.L.C.
$285
Lilly USA, LLC
$249
CSL Behring
$199
Pharmacyclics LLC, An AbbVie Company
$191
GENZYME CORPORATION
$180
Regeneron Healthcare Solutions, Inc.
$176
Alexion Pharmaceuticals, Inc.
$171
EISAI INC.
$168
Gilead Sciences, Inc.
$164
Takeda Pharmaceuticals U.S.A., Inc.
$163
Pharmacyclics LLC, an AbbVie Company
$150
GlaxoSmithKline, LLC.
$148
TAIHO ONCOLOGY, INC.
$147
Kyowa Kirin, Inc.
$137
Karyopharm Therapeutics Inc.
$112
SERVIER PHARMACEUTICALS LLC
$112
ABBVIE INC.
$109
Pharmacosmos Therapeutics Inc.
$105
Octapharma USA, Inc.
$103
Bayer Healthcare Pharmaceuticals Inc.
$98
Bayer HealthCare Pharmaceuticals Inc.
$98
Merck Sharp & Dohme Corporation
$98
G1 Therapeutics, Inc.
$93
MorphoSys, US Inc.
$93
ARRAY BIOPHARMA INC
$86
PharmaEssentia USA Corporation
$82
PUMA BIOTECHNOLOGY, INC.
$81
TerSera Therapeutics LLC
$79
Mirati Therapeutics, Inc.
$78
SEAGEN INC.
$78
Janssen Scientific Affairs, LLC
$78
SOBI, INC
$76
Apellis Pharmaceuticals, Inc.
$74
SUN PHARMACEUTICAL INDUSTRIES INC.
$69
Rigel Pharmaceuticals, Inc.
$54
Dova Pharmaceuticals
$53
Servier Pharmaceuticals LLC
$53
Alnylam Pharmaceuticals Inc.
$53
Puma Biotechnology, Inc.
$49
EMD Serono, Inc.
$45
Boehringer Ingelheim Pharmaceuticals, Inc.
$44
Coherus Biosciences Inc.
$33
Verity Pharmaceuticals Inc.
$32
Ipsen Biopharmaceuticals, Inc
$31
Taiho Oncology, Inc.
$29
Epizyme, Inc.,
$27
Heron Therapeutics, Inc.
$26
RECORDATI_RARE_DISEASES_INC.
$24
Deciphera Pharmaceuticals Inc.
$24
Tempus AI, Inc
$23
Organon LLC
$19
Agios Pharmaceuticals, Inc.
$19
Amneal Pharmaceuticals LLC
$18
Emmaus Medical, Inc.
$17
Blueprint Medicines Corporation
$17
BeiGene USA, Inc.
$17
Foundation Medicine, Inc.
$16
Acrotech Biopharma LLC
$14
Top 3 companies account for 16.0% of total payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · AUGTYRO · AVASTIN · AYVAKIT · Afstyla · Alecensa · Aliqopa · BAVENCIO · BELEODAQ · BESREMI · BLENREP · BOSULIF · BRAFTOVI · Blincyto · CALQUENCE · CINVANTI · COSELA · CYRAMZA · DARZALEX · Doptelet · ELAHERE · ELIQUIS · ELREXFIO · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · EXKIVITY · Empaveli · Endari · Enhertu · Epkinly · FOUNDATIONONE · FRUZAQLA · Fabhalta · GAZYVA · GILOTRIF · GIVLAARI · Gazyva · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Idelvion · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LOQTORZI · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · NERLYNX · NINLARO · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · ONTRUZANT · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · Onivyde · PADCEV · PANZYGA · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PYRUKYND · Padcev · Polivy · Pomalyst · Poteligeo · QINLOCK · Quzyttir · REBLOZYL · RETEVMO · RYBREVANT · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · SYLVANT · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECVAYLI · TEVIMBRA · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Tibsovo · Trelstar · Trodelvy · ULTOMIRIS · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · VONJO · Vanflyta · Venclexta · XALKORI · XPOVIO · XT CDX · XTANDI · Xofigo · Xospata · YONSA · ZEPZELCA · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 2% for physician assistant in FL.
Equivalent to $44 per 100 Medicare services performed
Geographic Context
Physician assistants within 10 mi
167
Per 100K population
43.1
County median income
$58,535
Nearest hospital
ADVENTHEALTH OCALA
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Legaspi is a mixed practice specialist, with above-average Medicare volume (top 0% in FL), with low-engagement industry engagement in the top 2% of FL peers.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Legaspi experienced with darbepoetin injection (aranesp) for anemia?
Based on Medicare claims data, Dr. Legaspi performed 9,000 darbepoetin injection (aranesp) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Legaspi receive payments from pharmaceutical companies?
Yes. Dr. Legaspi received a total of $11,124 from 73 companies across 545 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Legaspi's costs compare to other physician assistants in Ocala?
Dr. Legaspi's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Legaspi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Physician Assistants in Ocala
Browse physician assistants in Ocala ranked by procedure volume and transparency data.
Highest volume
Top Physician Assistants in FL
Physician assistants ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Physician Assistants in FL
Which FL physician assistants receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology